Literature DB >> 3335402

Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques.

M M Levine1, J B Kaper, D Herrington, G Losonsky, J G Morris, M L Clements, R E Black, B Tall, R Hall.   

Abstract

Vibrio cholerae O1 A-B- vaccine strain JBK 70 and A-B+ CVD 101 prepared by recombinant DNA techniques from pathogenic EI Tor Inaba N16961 and classical Ogawa 395, respectively, were fed to 38 volunteers in single doses of 10(4) to 10(10). Although severe diarrhea did not occur in any vaccine, more than one-half developed mild diarrhea. These attenuated strains colonized well and elicited prominent vibriocidal and antitoxic (CVD 101) antibody responses. Recipients of a single dose of JBK 70 were significantly protected when challenged with 10(6) wild-type N16961. Diarrhea occurred in 7 of 8 controls but in only 1 of 10 vaccines (P less than 0.003, 89% vaccine efficacy), demonstrating the potency of immune mechanisms that do not involve cholera antitoxin. Further derivatives were prepared to explore the pathogenesis of the residual diarrhea, considering that either intestinal colonization by the vaccine itself or accessory toxins might be responsible. CVD 102, an auxotrophic mutant of CVD 101, did not cause diarrhea but colonized poorly and elicited feeble immune responses. Derivatives of JBK 70 and CVD 101 (CVD 104 and 105) deleted of genes encoding the EI Tor hemolysin still caused mild diarrhea. Genetically engineered strains can be colonizing, highly immunogenic, and protective single-dose oral vaccines, but they must be further attenuated before they can be considered for use as public health tools.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3335402      PMCID: PMC259251          DOI: 10.1128/iai.56.1.161-167.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity.

Authors:  M M Levine; D R Nalin; J P Craig; D Hoover; E J Bergquist; D Waterman; H P Holley; R B Hornick; N P Pierce; J P Libonati
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

2.  Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine.

Authors:  R A Cash; S I Music; J P Libonati; J P Craig; N F Pierce; R B Hornick
Journal:  J Infect Dis       Date:  1974-10       Impact factor: 5.226

3.  A serological survey for cholear antibodies in rural east Pakistan. 1. The distribution of antibody in the control population of a cholera-vaccine field-trial area and the relation of antibody titre to the pattern of endemic cholera.

Authors:  W H Mosley; A S Benenson; R Barui
Journal:  Bull World Health Organ       Date:  1968       Impact factor: 9.408

Review 4.  Actions of cholera toxin and the prevention and treatment of cholera.

Authors:  J Holmgren
Journal:  Nature       Date:  1981-07-30       Impact factor: 49.962

5.  Duration of infection-derived immunity to cholera.

Authors:  M M Levine; R E Black; M L Clements; L Cisneros; D R Nalin; C R Young
Journal:  J Infect Dis       Date:  1981-06       Impact factor: 5.226

6.  Predisposition for cholera of individuals with O blood group. Possible evolutionary significance.

Authors:  R I Glass; J Holmgren; C E Haley; M R Khan; A M Svennerholm; B J Stoll; K M Belayet Hossain; R E Black; M Yunus; D Barua
Journal:  Am J Epidemiol       Date:  1985-06       Impact factor: 4.897

7.  The problem of emesis during oral glucose-electrolytes therapy given from the onset of severe cholera.

Authors:  D R Nalin; M M Levine; R B Hornick; E J Bergquist; D Hoover; H P Holley; D Waterman; J VanBlerk; S Matheny; S Sotman; M Rennels
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

8.  Selective vs. nonselective media and direct plating vs. enrichment technique in isolation of Vibrio cholerae: recommendations for clinical laboratories.

Authors:  M B Rennels; M M Levine; V Daya; P Angle; C Young
Journal:  J Infect Dis       Date:  1980-09       Impact factor: 5.226

9.  Genetic susceptibility to cholera.

Authors:  M M Levine; D R Nalin; M B Rennels; R B Hornick; S Sotman; G Van Blerk; T P Hughes; S O'Donnell; D Barua
Journal:  Ann Hum Biol       Date:  1979 Jul-Aug       Impact factor: 1.533

10.  Antibacterial and antitoxin responses in the serum and milk of cholera patients.

Authors:  A S Majumdar; P Dutta; D Dutta; A C Ghose
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

View more
  94 in total

1.  Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision.

Authors:  S L Chiang; J J Mekalanos
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.

Authors:  K L Kotloff; S S Wasserman; S O'Donnell; G A Losonsky; S J Cryz; M M Levine
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

3.  Role of toll-like receptor 4 in the proinflammatory response to Vibrio cholerae O1 El tor strains deficient in production of cholera toxin and accessory toxins.

Authors:  G Kenneth Haines; Blayne Amir Sayed; Melissa S Rohrer; Verena Olivier; Karla J Fullner Satchell
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Induction of interleukin-8 in T84 cells by Vibrio cholerae.

Authors:  Xin Zhou; Da Q Gao; Jane Michalski; Jorge A Benitez; James B Kaper
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Relatedness of a periplasmic, broad-specificity RNase from Aeromonas hydrophila to RNase I of Escherichia coli and to a family of eukaryotic RNases.

Authors:  D Favre; P K Ngai; K N Timmis
Journal:  J Bacteriol       Date:  1993-06       Impact factor: 3.490

6.  Quantitative detection of Vibrio cholera toxin by real-time and dynamic cytotoxicity monitoring.

Authors:  Dazhi Jin; Yun Luo; Min Zheng; Haijing Li; Jing Zhang; Melinda Stampfl; Xiao Xu; Gangqiang Ding; Yanjun Zhang; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2013-09-18       Impact factor: 5.948

7.  Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

Authors:  C C Häse; L S Thai; M Boesman-Finkelstein; V L Mar; W N Burnette; H R Kaslow; L A Stevens; J Moss; R A Finkelstein
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

8.  An in vivo expression technology screen for Vibrio cholerae genes expressed in human volunteers.

Authors:  Mary-Jane Lombardo; Jane Michalski; Hector Martinez-Wilson; Cara Morin; Tamara Hilton; Carlos G Osorio; James P Nataro; Carol O Tacket; Andrew Camilli; James B Kaper
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-06       Impact factor: 11.205

9.  Detection of Escherichia coli, Salmonella spp., Shigella spp., Yersinia enterocolitica, Vibrio cholerae, and Campylobacter spp. enteropathogens by 3-reaction multiplex polymerase chain reaction.

Authors:  Oscar G Gómez-Duarte; Jing Bai; Elizabeth Newell
Journal:  Diagn Microbiol Infect Dis       Date:  2008-11-06       Impact factor: 2.803

10.  The extracellular cytolysin of Vibrio vulnificus: inactivation and relationship to virulence in mice.

Authors:  A C Wright; J G Morris
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.